Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer-Reference-Cited by-同舟云学术

Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer

Published:2007-04-01 Issue:4 Volume:12 Page:443-450
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Los Maartje¹,Roodhart Jeanine M. L.¹,Voest Emile E.¹

Affiliation:

1. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the safety of using bevacizumab in clinical practice.Explain the benefit of adding bevacizumab to chemotherapy in colorectal cancer.Discuss mechanisms of targeting the VEGF/VEGFR pathway. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-4-443

Reference45 articles.

1. Vascular endothelial growth factor is a secreted angiogenic mitogen;Leung;Science,1989

2. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele;Carmeliet;Nature,1996

3. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene;Ferrara;Nature,1996

4. Molecular and biological properties of the vascular endothelial growth factor family of proteins;Ferrara;Endocr Rev,1992

5. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms;Cardiovascular Drugs and Therapy;2024-03-16

2. In-silico modelling of the mitogen-activated protein kinase (MAPK) pathway in colorectal cancer: mutations and targeted therapy;Frontiers in Systems Biology;2023-08-23

3. In-silico modelling of the mitogen-activated kinase (MAPK) pathway in colorectal cancer: mutations and targeted therapy;2023-04-20

4. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity;Molecular Therapy;2023-01

5. Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications;Cancers;2022-07-05